nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexrazoxane—TOP2A—Methyltestosterone—Prednisone—systemic scleroderma	0.00475	1	CbGdCrCtD
Dexrazoxane—Nervous system disorder—Leflunomide—systemic scleroderma	0.0018	0.00181	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Leflunomide—systemic scleroderma	0.00179	0.00181	CcSEcCtD
Dexrazoxane—Pruritus—Mometasone—systemic scleroderma	0.00179	0.0018	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Lisinopril—systemic scleroderma	0.00179	0.0018	CcSEcCtD
Dexrazoxane—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00178	0.0018	CcSEcCtD
Dexrazoxane—Anaemia—Lisinopril—systemic scleroderma	0.00178	0.0018	CcSEcCtD
Dexrazoxane—Skin disorder—Leflunomide—systemic scleroderma	0.00178	0.00179	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00177	0.00178	CcSEcCtD
Dexrazoxane—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00176	0.00177	CcSEcCtD
Dexrazoxane—Abdominal pain—Captopril—systemic scleroderma	0.00176	0.00177	CcSEcCtD
Dexrazoxane—Body temperature increased—Captopril—systemic scleroderma	0.00176	0.00177	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00175	0.00176	CcSEcCtD
Dexrazoxane—Anorexia—Leflunomide—systemic scleroderma	0.00175	0.00176	CcSEcCtD
Dexrazoxane—Nausea—Pentoxifylline—systemic scleroderma	0.00174	0.00176	CcSEcCtD
Dexrazoxane—Malaise—Lisinopril—systemic scleroderma	0.00174	0.00175	CcSEcCtD
Dexrazoxane—Infection—Mycophenolic acid—systemic scleroderma	0.00174	0.00175	CcSEcCtD
Dexrazoxane—Diarrhoea—Mometasone—systemic scleroderma	0.00173	0.00174	CcSEcCtD
Dexrazoxane—Syncope—Lisinopril—systemic scleroderma	0.00173	0.00174	CcSEcCtD
Dexrazoxane—Leukopenia—Lisinopril—systemic scleroderma	0.00173	0.00174	CcSEcCtD
Dexrazoxane—Shock—Mycophenolic acid—systemic scleroderma	0.00172	0.00173	CcSEcCtD
Dexrazoxane—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.00172	0.00173	CcSEcCtD
Dexrazoxane—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00171	0.00173	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00171	0.00172	CcSEcCtD
Dexrazoxane—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.0017	0.00171	CcSEcCtD
Dexrazoxane—Skin disorder—Mycophenolic acid—systemic scleroderma	0.0017	0.00171	CcSEcCtD
Dexrazoxane—Loss of consciousness—Lisinopril—systemic scleroderma	0.00169	0.00171	CcSEcCtD
Dexrazoxane—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00169	0.0017	CcSEcCtD
Dexrazoxane—Cough—Lisinopril—systemic scleroderma	0.00168	0.0017	CcSEcCtD
Dexrazoxane—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.00168	0.00169	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00167	0.00169	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00167	0.00168	CcSEcCtD
Dexrazoxane—Anorexia—Mycophenolic acid—systemic scleroderma	0.00167	0.00168	CcSEcCtD
Dexrazoxane—Insomnia—Leflunomide—systemic scleroderma	0.00166	0.00167	CcSEcCtD
Dexrazoxane—Myalgia—Lisinopril—systemic scleroderma	0.00164	0.00165	CcSEcCtD
Dexrazoxane—Dyspnoea—Leflunomide—systemic scleroderma	0.00163	0.00165	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00163	0.00164	CcSEcCtD
Dexrazoxane—Discomfort—Lisinopril—systemic scleroderma	0.00162	0.00163	CcSEcCtD
Dexrazoxane—Vomiting—Mometasone—systemic scleroderma	0.00161	0.00162	CcSEcCtD
Dexrazoxane—Dry mouth—Lisinopril—systemic scleroderma	0.00161	0.00162	CcSEcCtD
Dexrazoxane—Feeling abnormal—Azathioprine—systemic scleroderma	0.0016	0.00161	CcSEcCtD
Dexrazoxane—Asthenia—Captopril—systemic scleroderma	0.00159	0.00161	CcSEcCtD
Dexrazoxane—Decreased appetite—Leflunomide—systemic scleroderma	0.00159	0.0016	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00159	0.0016	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00159	0.0016	CcSEcCtD
Dexrazoxane—Headache—Mometasone—systemic scleroderma	0.00159	0.0016	CcSEcCtD
Dexrazoxane—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00158	0.0016	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00158	0.00159	CcSEcCtD
Dexrazoxane—Insomnia—Mycophenolic acid—systemic scleroderma	0.00158	0.00159	CcSEcCtD
Dexrazoxane—Fatigue—Leflunomide—systemic scleroderma	0.00158	0.00159	CcSEcCtD
Dexrazoxane—Pruritus—Captopril—systemic scleroderma	0.00157	0.00158	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.00157	0.00158	CcSEcCtD
Dexrazoxane—Constipation—Leflunomide—systemic scleroderma	0.00157	0.00158	CcSEcCtD
Dexrazoxane—Pain—Leflunomide—systemic scleroderma	0.00157	0.00158	CcSEcCtD
Dexrazoxane—Infection—Lisinopril—systemic scleroderma	0.00156	0.00158	CcSEcCtD
Dexrazoxane—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.00156	0.00157	CcSEcCtD
Dexrazoxane—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00156	0.00157	CcSEcCtD
Dexrazoxane—Somnolence—Mycophenolic acid—systemic scleroderma	0.00155	0.00157	CcSEcCtD
Dexrazoxane—Shock—Lisinopril—systemic scleroderma	0.00155	0.00156	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00154	0.00155	CcSEcCtD
Dexrazoxane—Neutropenia—Prednisone—systemic scleroderma	0.00154	0.00155	CcSEcCtD
Dexrazoxane—Abdominal pain—Azathioprine—systemic scleroderma	0.00153	0.00155	CcSEcCtD
Dexrazoxane—Body temperature increased—Azathioprine—systemic scleroderma	0.00153	0.00155	CcSEcCtD
Dexrazoxane—Skin disorder—Lisinopril—systemic scleroderma	0.00153	0.00154	CcSEcCtD
Dexrazoxane—Malaise—Mycophenolate mofetil—systemic scleroderma	0.00152	0.00154	CcSEcCtD
Dexrazoxane—Diarrhoea—Captopril—systemic scleroderma	0.00152	0.00153	CcSEcCtD
Dexrazoxane—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00152	0.00153	CcSEcCtD
Dexrazoxane—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00152	0.00153	CcSEcCtD
Dexrazoxane—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00151	0.00152	CcSEcCtD
Dexrazoxane—Feeling abnormal—Leflunomide—systemic scleroderma	0.00151	0.00152	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00151	0.00152	CcSEcCtD
Dexrazoxane—Fatigue—Mycophenolic acid—systemic scleroderma	0.00151	0.00152	CcSEcCtD
Dexrazoxane—Nausea—Mometasone—systemic scleroderma	0.0015	0.00151	CcSEcCtD
Dexrazoxane—Anorexia—Lisinopril—systemic scleroderma	0.0015	0.00151	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.0015	0.00151	CcSEcCtD
Dexrazoxane—Constipation—Mycophenolic acid—systemic scleroderma	0.00149	0.00151	CcSEcCtD
Dexrazoxane—Pain—Mycophenolic acid—systemic scleroderma	0.00149	0.00151	CcSEcCtD
Dexrazoxane—Weight decreased—Prednisone—systemic scleroderma	0.00149	0.0015	CcSEcCtD
Dexrazoxane—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00149	0.0015	CcSEcCtD
Dexrazoxane—Cough—Mycophenolate mofetil—systemic scleroderma	0.00147	0.00149	CcSEcCtD
Dexrazoxane—Dizziness—Captopril—systemic scleroderma	0.00147	0.00148	CcSEcCtD
Dexrazoxane—Depression—Prednisone—systemic scleroderma	0.00146	0.00147	CcSEcCtD
Dexrazoxane—Urticaria—Leflunomide—systemic scleroderma	0.00146	0.00147	CcSEcCtD
Dexrazoxane—Abdominal pain—Leflunomide—systemic scleroderma	0.00145	0.00146	CcSEcCtD
Dexrazoxane—Body temperature increased—Leflunomide—systemic scleroderma	0.00145	0.00146	CcSEcCtD
Dexrazoxane—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00144	0.00145	CcSEcCtD
Dexrazoxane—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00145	CcSEcCtD
Dexrazoxane—Breast disorder—Methotrexate—systemic scleroderma	0.00144	0.00145	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00143	0.00144	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00143	0.00144	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00143	0.00144	CcSEcCtD
Dexrazoxane—Insomnia—Lisinopril—systemic scleroderma	0.00142	0.00143	CcSEcCtD
Dexrazoxane—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00143	CcSEcCtD
Dexrazoxane—Vomiting—Captopril—systemic scleroderma	0.00141	0.00142	CcSEcCtD
Dexrazoxane—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00141	0.00142	CcSEcCtD
Dexrazoxane—Dyspnoea—Lisinopril—systemic scleroderma	0.0014	0.00141	CcSEcCtD
Dexrazoxane—Somnolence—Lisinopril—systemic scleroderma	0.0014	0.00141	CcSEcCtD
Dexrazoxane—Headache—Captopril—systemic scleroderma	0.00139	0.0014	CcSEcCtD
Dexrazoxane—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00138	0.00139	CcSEcCtD
Dexrazoxane—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00138	0.00139	CcSEcCtD
Dexrazoxane—Infection—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00138	CcSEcCtD
Dexrazoxane—Decreased appetite—Lisinopril—systemic scleroderma	0.00137	0.00138	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00136	0.00137	CcSEcCtD
Dexrazoxane—Fatigue—Lisinopril—systemic scleroderma	0.00136	0.00137	CcSEcCtD
Dexrazoxane—Shock—Mycophenolate mofetil—systemic scleroderma	0.00136	0.00137	CcSEcCtD
Dexrazoxane—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00136	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00136	CcSEcCtD
Dexrazoxane—Pain—Lisinopril—systemic scleroderma	0.00135	0.00136	CcSEcCtD
Dexrazoxane—Constipation—Lisinopril—systemic scleroderma	0.00135	0.00136	CcSEcCtD
Dexrazoxane—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00134	0.00135	CcSEcCtD
Dexrazoxane—Diarrhoea—Azathioprine—systemic scleroderma	0.00133	0.00134	CcSEcCtD
Dexrazoxane—Haemoglobin—Prednisone—systemic scleroderma	0.00132	0.00133	CcSEcCtD
Dexrazoxane—Nausea—Captopril—systemic scleroderma	0.00132	0.00133	CcSEcCtD
Dexrazoxane—Haemorrhage—Prednisone—systemic scleroderma	0.00132	0.00133	CcSEcCtD
Dexrazoxane—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00131	0.00132	CcSEcCtD
Dexrazoxane—Asthenia—Leflunomide—systemic scleroderma	0.00131	0.00132	CcSEcCtD
Dexrazoxane—Pancytopenia—Methotrexate—systemic scleroderma	0.0013	0.00131	CcSEcCtD
Dexrazoxane—Feeling abnormal—Lisinopril—systemic scleroderma	0.0013	0.00131	CcSEcCtD
Dexrazoxane—Pruritus—Leflunomide—systemic scleroderma	0.0013	0.00131	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Prednisone—systemic scleroderma	0.00129	0.0013	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00129	0.0013	CcSEcCtD
Dexrazoxane—Neutropenia—Methotrexate—systemic scleroderma	0.00128	0.00129	CcSEcCtD
Dexrazoxane—Dizziness—Azathioprine—systemic scleroderma	0.00128	0.00129	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00127	CcSEcCtD
Dexrazoxane—Asthenia—Mycophenolic acid—systemic scleroderma	0.00125	0.00126	CcSEcCtD
Dexrazoxane—Diarrhoea—Leflunomide—systemic scleroderma	0.00125	0.00126	CcSEcCtD
Dexrazoxane—Urticaria—Lisinopril—systemic scleroderma	0.00125	0.00126	CcSEcCtD
Dexrazoxane—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00126	CcSEcCtD
Dexrazoxane—Abdominal pain—Lisinopril—systemic scleroderma	0.00124	0.00125	CcSEcCtD
Dexrazoxane—Body temperature increased—Lisinopril—systemic scleroderma	0.00124	0.00125	CcSEcCtD
Dexrazoxane—Pruritus—Mycophenolic acid—systemic scleroderma	0.00124	0.00125	CcSEcCtD
Dexrazoxane—Vomiting—Azathioprine—systemic scleroderma	0.00123	0.00124	CcSEcCtD
Dexrazoxane—Pneumonia—Methotrexate—systemic scleroderma	0.00123	0.00124	CcSEcCtD
Dexrazoxane—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00123	0.00124	CcSEcCtD
Dexrazoxane—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00123	0.00124	CcSEcCtD
Dexrazoxane—Infestation NOS—Methotrexate—systemic scleroderma	0.00122	0.00123	CcSEcCtD
Dexrazoxane—Infestation—Methotrexate—systemic scleroderma	0.00122	0.00123	CcSEcCtD
Dexrazoxane—Depression—Methotrexate—systemic scleroderma	0.00122	0.00123	CcSEcCtD
Dexrazoxane—Headache—Azathioprine—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Dexrazoxane—Dizziness—Leflunomide—systemic scleroderma	0.00121	0.00122	CcSEcCtD
Dexrazoxane—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.0012	0.00121	CcSEcCtD
Dexrazoxane—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Dexrazoxane—Stomatitis—Methotrexate—systemic scleroderma	0.00119	0.0012	CcSEcCtD
Dexrazoxane—Angiopathy—Prednisone—systemic scleroderma	0.00119	0.0012	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00119	0.0012	CcSEcCtD
Dexrazoxane—Pain—Mycophenolate mofetil—systemic scleroderma	0.00118	0.00119	CcSEcCtD
Dexrazoxane—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00118	0.00119	CcSEcCtD
Dexrazoxane—Vomiting—Leflunomide—systemic scleroderma	0.00116	0.00117	CcSEcCtD
Dexrazoxane—Alopecia—Prednisone—systemic scleroderma	0.00116	0.00117	CcSEcCtD
Dexrazoxane—Dizziness—Mycophenolic acid—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Dexrazoxane—Mental disorder—Prednisone—systemic scleroderma	0.00115	0.00116	CcSEcCtD
Dexrazoxane—Nausea—Azathioprine—systemic scleroderma	0.00115	0.00116	CcSEcCtD
Dexrazoxane—Headache—Leflunomide—systemic scleroderma	0.00115	0.00116	CcSEcCtD
Dexrazoxane—Erythema—Prednisone—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Dexrazoxane—Malnutrition—Prednisone—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Dexrazoxane—Agranulocytosis—Methotrexate—systemic scleroderma	0.00114	0.00115	CcSEcCtD
Dexrazoxane—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00115	CcSEcCtD
Dexrazoxane—Asthenia—Lisinopril—systemic scleroderma	0.00113	0.00114	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00114	CcSEcCtD
Dexrazoxane—Pruritus—Lisinopril—systemic scleroderma	0.00111	0.00112	CcSEcCtD
Dexrazoxane—Vomiting—Mycophenolic acid—systemic scleroderma	0.00111	0.00112	CcSEcCtD
Dexrazoxane—Haemoglobin—Methotrexate—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Dexrazoxane—Haemorrhage—Methotrexate—systemic scleroderma	0.0011	0.00111	CcSEcCtD
Dexrazoxane—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Dexrazoxane—Headache—Mycophenolic acid—systemic scleroderma	0.00109	0.0011	CcSEcCtD
Dexrazoxane—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00109	0.0011	CcSEcCtD
Dexrazoxane—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00109	0.0011	CcSEcCtD
Dexrazoxane—Nausea—Leflunomide—systemic scleroderma	0.00109	0.0011	CcSEcCtD
Dexrazoxane—Diarrhoea—Lisinopril—systemic scleroderma	0.00108	0.00109	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Prednisone—systemic scleroderma	0.00106	0.00107	CcSEcCtD
Dexrazoxane—Anaemia—Prednisone—systemic scleroderma	0.00106	0.00107	CcSEcCtD
Dexrazoxane—Dizziness—Lisinopril—systemic scleroderma	0.00104	0.00105	CcSEcCtD
Dexrazoxane—Nausea—Mycophenolic acid—systemic scleroderma	0.00104	0.00105	CcSEcCtD
Dexrazoxane—Malaise—Prednisone—systemic scleroderma	0.00103	0.00104	CcSEcCtD
Dexrazoxane—Syncope—Prednisone—systemic scleroderma	0.00103	0.00104	CcSEcCtD
Dexrazoxane—Cardiac disorder—Methotrexate—systemic scleroderma	0.00102	0.00103	CcSEcCtD
Dexrazoxane—Loss of consciousness—Prednisone—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Dexrazoxane—Vomiting—Lisinopril—systemic scleroderma	0.001	0.00101	CcSEcCtD
Dexrazoxane—Angiopathy—Methotrexate—systemic scleroderma	0.000998	0.00101	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000991	0.000999	CcSEcCtD
Dexrazoxane—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000989	0.000997	CcSEcCtD
Dexrazoxane—Headache—Lisinopril—systemic scleroderma	0.000986	0.000994	CcSEcCtD
Dexrazoxane—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000976	0.000983	CcSEcCtD
Dexrazoxane—Myalgia—Prednisone—systemic scleroderma	0.000975	0.000983	CcSEcCtD
Dexrazoxane—Alopecia—Methotrexate—systemic scleroderma	0.000972	0.000979	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000968	0.000976	CcSEcCtD
Dexrazoxane—Discomfort—Prednisone—systemic scleroderma	0.000963	0.000971	CcSEcCtD
Dexrazoxane—Mental disorder—Methotrexate—systemic scleroderma	0.000963	0.000971	CcSEcCtD
Dexrazoxane—Malnutrition—Methotrexate—systemic scleroderma	0.000957	0.000965	CcSEcCtD
Dexrazoxane—Erythema—Methotrexate—systemic scleroderma	0.000957	0.000965	CcSEcCtD
Dexrazoxane—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000943	0.000951	CcSEcCtD
Dexrazoxane—Nausea—Lisinopril—systemic scleroderma	0.000935	0.000942	CcSEcCtD
Dexrazoxane—Infection—Prednisone—systemic scleroderma	0.000929	0.000936	CcSEcCtD
Dexrazoxane—Shock—Prednisone—systemic scleroderma	0.00092	0.000927	CcSEcCtD
Dexrazoxane—Nervous system disorder—Prednisone—systemic scleroderma	0.000917	0.000924	CcSEcCtD
Dexrazoxane—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000912	0.000919	CcSEcCtD
Dexrazoxane—Skin disorder—Prednisone—systemic scleroderma	0.000908	0.000915	CcSEcCtD
Dexrazoxane—Anorexia—Prednisone—systemic scleroderma	0.000891	0.000898	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000888	0.000895	CcSEcCtD
Dexrazoxane—Anaemia—Methotrexate—systemic scleroderma	0.000885	0.000892	CcSEcCtD
Dexrazoxane—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000877	0.000884	CcSEcCtD
Dexrazoxane—Headache—Mycophenolate mofetil—systemic scleroderma	0.000864	0.000871	CcSEcCtD
Dexrazoxane—Malaise—Methotrexate—systemic scleroderma	0.000863	0.00087	CcSEcCtD
Dexrazoxane—Leukopenia—Methotrexate—systemic scleroderma	0.000857	0.000863	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000852	0.000858	CcSEcCtD
Dexrazoxane—Insomnia—Prednisone—systemic scleroderma	0.000845	0.000852	CcSEcCtD
Dexrazoxane—Cough—Methotrexate—systemic scleroderma	0.000835	0.000842	CcSEcCtD
Dexrazoxane—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000819	0.000825	CcSEcCtD
Dexrazoxane—Myalgia—Methotrexate—systemic scleroderma	0.000815	0.000821	CcSEcCtD
Dexrazoxane—Decreased appetite—Prednisone—systemic scleroderma	0.000813	0.000819	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000809	0.000816	CcSEcCtD
Dexrazoxane—Fatigue—Prednisone—systemic scleroderma	0.000806	0.000812	CcSEcCtD
Dexrazoxane—Discomfort—Methotrexate—systemic scleroderma	0.000805	0.000811	CcSEcCtD
Dexrazoxane—Constipation—Prednisone—systemic scleroderma	0.000799	0.000805	CcSEcCtD
Dexrazoxane—Infection—Methotrexate—systemic scleroderma	0.000776	0.000782	CcSEcCtD
Dexrazoxane—Feeling abnormal—Prednisone—systemic scleroderma	0.00077	0.000776	CcSEcCtD
Dexrazoxane—Nervous system disorder—Methotrexate—systemic scleroderma	0.000766	0.000772	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000765	0.000771	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000764	0.00077	CcSEcCtD
Dexrazoxane—Skin disorder—Methotrexate—systemic scleroderma	0.000759	0.000765	CcSEcCtD
Dexrazoxane—Anorexia—Methotrexate—systemic scleroderma	0.000745	0.00075	CcSEcCtD
Dexrazoxane—Urticaria—Prednisone—systemic scleroderma	0.000743	0.000748	CcSEcCtD
Dexrazoxane—Body temperature increased—Prednisone—systemic scleroderma	0.000739	0.000745	CcSEcCtD
Dexrazoxane—Abdominal pain—Prednisone—systemic scleroderma	0.000739	0.000745	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000712	0.000717	CcSEcCtD
Dexrazoxane—Insomnia—Methotrexate—systemic scleroderma	0.000707	0.000712	CcSEcCtD
Dexrazoxane—Dyspnoea—Methotrexate—systemic scleroderma	0.000696	0.000702	CcSEcCtD
Dexrazoxane—Somnolence—Methotrexate—systemic scleroderma	0.000694	0.0007	CcSEcCtD
Dexrazoxane—Decreased appetite—Methotrexate—systemic scleroderma	0.000679	0.000684	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000674	0.00068	CcSEcCtD
Dexrazoxane—Fatigue—Methotrexate—systemic scleroderma	0.000673	0.000679	CcSEcCtD
Dexrazoxane—Asthenia—Prednisone—systemic scleroderma	0.000671	0.000676	CcSEcCtD
Dexrazoxane—Pain—Methotrexate—systemic scleroderma	0.000668	0.000673	CcSEcCtD
Dexrazoxane—Pruritus—Prednisone—systemic scleroderma	0.000661	0.000666	CcSEcCtD
Dexrazoxane—Feeling abnormal—Methotrexate—systemic scleroderma	0.000644	0.000649	CcSEcCtD
Dexrazoxane—Diarrhoea—Prednisone—systemic scleroderma	0.00064	0.000644	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000639	0.000644	CcSEcCtD
Dexrazoxane—Urticaria—Methotrexate—systemic scleroderma	0.000621	0.000625	CcSEcCtD
Dexrazoxane—Dizziness—Prednisone—systemic scleroderma	0.000618	0.000623	CcSEcCtD
Dexrazoxane—Abdominal pain—Methotrexate—systemic scleroderma	0.000618	0.000622	CcSEcCtD
Dexrazoxane—Body temperature increased—Methotrexate—systemic scleroderma	0.000618	0.000622	CcSEcCtD
Dexrazoxane—TOP2B—connective tissue—systemic scleroderma	0.000597	0.205	CbGeAlD
Dexrazoxane—Vomiting—Prednisone—systemic scleroderma	0.000594	0.000599	CcSEcCtD
Dexrazoxane—Headache—Prednisone—systemic scleroderma	0.000586	0.00059	CcSEcCtD
Dexrazoxane—Asthenia—Methotrexate—systemic scleroderma	0.00056	0.000565	CcSEcCtD
Dexrazoxane—Nausea—Prednisone—systemic scleroderma	0.000555	0.000559	CcSEcCtD
Dexrazoxane—Pruritus—Methotrexate—systemic scleroderma	0.000553	0.000557	CcSEcCtD
Dexrazoxane—TOP2B—smooth muscle tissue—systemic scleroderma	0.000546	0.188	CbGeAlD
Dexrazoxane—Diarrhoea—Methotrexate—systemic scleroderma	0.000534	0.000539	CcSEcCtD
Dexrazoxane—Dizziness—Methotrexate—systemic scleroderma	0.000517	0.000521	CcSEcCtD
Dexrazoxane—Vomiting—Methotrexate—systemic scleroderma	0.000497	0.000501	CcSEcCtD
Dexrazoxane—Headache—Methotrexate—systemic scleroderma	0.000489	0.000493	CcSEcCtD
Dexrazoxane—Nausea—Methotrexate—systemic scleroderma	0.000464	0.000468	CcSEcCtD
Dexrazoxane—TOP2B—digestive system—systemic scleroderma	0.000431	0.148	CbGeAlD
Dexrazoxane—TOP2B—tendon—systemic scleroderma	0.000411	0.141	CbGeAlD
Dexrazoxane—TOP2B—lung—systemic scleroderma	0.00036	0.124	CbGeAlD
Dexrazoxane—TOP2A—tendon—systemic scleroderma	0.000302	0.104	CbGeAlD
Dexrazoxane—TOP2A—lung—systemic scleroderma	0.000265	0.091	CbGeAlD
